The Evolution of Precision Medicine- Entering the Era of Multi-omics
Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Washington DC, USA
Cracking open the undruggable RAS: A Clinical Perspective
Associate Vice President of Clinical Research, University of Texas M.D. Anderson Cancer Center
Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, USA.
Apocrine breast carcinoma from biomarkers to therapy
Director of Anatomic Pathology, University of Oklahoma Health Sciences Center, Oklahoma, USA.
Solid Tumors: Immuno-Oncology
Director, Cancer Vaccine Institute, University of Washington (UW)
Director, Institute of Translational Health Sciences UW, Seattle, WA, USA
Age of combination therapy in the treatment of advanced RCC: can we do it better?
Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA.
Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution
National Center for Biotechnology Information, National Library of Medicine,
National Institutes of Health, Bethesda, MD, USA
Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors
Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK
Combination of integrated genomics with ex vivo microcancer drug screens to individualize brain cancer therapy
Cell Biology Program Director, Cell Adhesion and Metastasis Laboratory
Mayo Clinic Cancer Center, Jacksonville, FL, USA
Patient selection for PARP Inhibitors: Genomic Considerations
Tulane Medical School Department of Internal Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana,USA.
Potential prostate cancer targeting strategies revealed by integrative proteogenomics
School of Medicine, Institute of Biomedicine, University of Eastern Finland
Kuopio, Finland
Importance of Genomics in Prostate Cancer: Role of PARPi in CRPC
Division Chief, Solid Tumor Oncology University Hospitals Seidman Cancer Center
Cleveland, OH, USA
The Third Dimension in Prostate Cancer
University of Colorado, AMC Department of Pathology, Aurora, CO, US
The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells
Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy
RWTH Aachen University Hospital, Dental Materials and Biomaterials Research, Aachen, Germany
TKIs in Chronic Myelogenous Leukemia (CML) Therapy: Monitoring & Mechanisms of resistance
Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
Department of Pathology, Sant’Andrea University Hospital, Rome, Italy
Identification of distinct immune signatures in malignant pleural mesothelioma
Director, Oncology Research and Immuno-monitoring Core (ORION)
Director, Translational Molecular Pathology and Immunoprofiling Lab,
UT MD Anderson Cancer Center, Houston, TX, US
Imaging of tumor acidosis for monitoring response to novel anticancer therapies
Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR)
Torino, Italy
Outcome of patients receiving 2nd line or later CML Therapy
Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA
Molecular Testing and Liquid Biopsy for Ovarian Cancer
UCLA Medical Center, Santa Monica, LA, USA
Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature
Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy
Second-line Therapy & Beyond in Metastatic Urothelial Carcinoma
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio
Mesenchymal stem/stromal cells and the tumor tissue microenvironment
Soochow University Institutes for Translational Medicine &
Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China
Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma
Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy
Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden
Department of Biology, California State University Northridge (CSUN)
Los Angeles, California
The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies
IRCCS Neuromed, Pozzilli & University of Insubria Varese, Italy
Glucocorticoids and Angiogenesis
Yale School of Medicine, New Haven, CT, USA
Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response
Houston Methodist Research Institute, Houston, USA
School of Medicine at Swansea University, Wales, UK
Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function
Director, Allen Discovery Center at Tufts and Tufts Center for Regenerative and Developmental Biology, Tufts University, Medford, USA.
Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data
Department of Physics, Chuo University, Tokyo, Japan
Targeting glycosaminoglycans in solid tumors
Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre
Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity
Department of Internal Medicine V (Hematology and Oncology)
Medizinische Universität Innsbruck, Innsbruck, Austria
MET as a druggable target in solid tumors
Department of BioMedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, US
The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology
Ex. Scientific Director, Regina Elena Institute (IRE), Rome, Italy.
A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients
Director, Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, USA
Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance
Unit of Clinical Pharmacology and Pharmacogenetics, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Prostate Cancer PARP Combination Clinical Trials
Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan
The Role of p63 in the Female Germline Fidelity and Related Cancers
Director of Department & Professor of Molecular Biology, Faculty of Medicine, University of Rome – Tor Vergata, Rome, Italy.
Two retrospective studies on gender differences: chemotherapy toxicities in patients affected by colorectal and pancreatic cancers
Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy
Ongoing Clinical Trials in Advanced Urothelial Carcinoma & Future Directions
Division of Hematology and Oncology, University of California San Francisco, US
Do we need new TKIs for CML therapy?
Division of Internal Medicine and Haematology, University of Turin, Turin, Italy
Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy
Designing a Multi-Epitope Vaccine Against Cancer-Testis Antigens in Non-Small Cell Lung Cancer: an In Silico Approach (Poster Talk)
Polytechnic University of the Philippines, Philippines.
A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma (Poster Talk)
Sun Yat-sen University Cancer center, Guangzhou, China
Prognostic factors on her2-positive metastatic breast cancer patients treated with trastuzumab emtansine – real-world study (Poster Talk)
Oncology Institute of Coimbra, Coimbra, Portugal
Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib (Poster Talk)
University of Rijeka, Department of Biotechnology, Rijeka, Croatia
Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer (Poster Talk)
Universitat Autònoma de Barcelona, Barcelona, Spain
★ Agenda is being updated regularly
